Trials / Completed
CompletedNCT04821687
A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD
A Randomized, Parallel Group, Multicenter, Prospective, Open-label, Exploratory, Phase 4 Study to Evaluate the Add-on Effect of Opicapone 50 mg or Levodopa 100 mg as First Strategy for the Treatment of Wearing-off in Patients With Parkinson's Disease
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 169 (actual)
- Sponsor
- SK Chemicals Co., Ltd. · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
A Study to evaluate the add-on efficacy and safety of opicapone 50 mg or an extra dose of L-DOPA 100 mg for the treatment of wearing-off in patients with PD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ongentys 50mg | Opicapone 50mg will be added to current and stable therapy of L-DOPA/DDCI |
| DRUG | Madopar Tab. 125 or Perkin Tab. 25-100mg | Madopar Tab. 125 or Perkin Tab. 25-100mg will be added to current and stable therapy of L-DOPA/DDCI |
Timeline
- Start date
- 2021-06-17
- Primary completion
- 2022-08-18
- Completion
- 2022-08-18
- First posted
- 2021-03-29
- Last updated
- 2023-06-01
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04821687. Inclusion in this directory is not an endorsement.